NEW YORK, Oct. 7, 2019 /PRNewswire/ -- Equity research is
published in the framework of Frost's Independent Equity Research
Program. This type of equity research is trusted by investors as it
is unbiased and analysts have no financial interest in the
stock. You can explore all of the companies
we cover HERE and contact us at no cost to learn more about
them or to tell us about companies you want covered:
equity.research@frost.com.
Summary of Q2 Highlights:
Itamar Medical: (NASDAQ / TASE: ITMR)
Revolutionary technology enables cardiologists to make better
decisions and leads to 21% revenue increase in Q2; Itamar Medical
continues its geo expansion into new territories in the US;
receives FDA approval for first disposable home sleep apnea test.
Full Report HERE
Entera: (NASDAQ: ENTX)
Turning Injections to Pills. Successful Phase II PK/PD.
Announced on Positive Results from its Phase 2 PK/PD Study of Oral
PTH (1-34) in Patients with Hypoparathyroidism. The company
developed a delivery platform that allows oral delivery of large
molecules and biologics that are currently given by injection;
Entera Bio is on track with its two drugs in clinical phases. Full
Report HERE
Allot (NASDAQ / TASE: ALLT)
Significant Increased Revenue Expected for Allot. Allot Allows
Telecom Providers to Leverage Their Networks for Increased
Revenues; We view Allot`s Mobile Network Security operations as a
growth engine for the company's revenues in the coming years; we
initiate coverage on Allot at a share price target of $12.0. Full Report HERE
Kadimastem (TASE: KDST)
ALS Treatment: Positive High Potential Results. Positive interim
results from first ALS cohort (Cohort A) indicating significant
slowdown in ALS deterioration, Kadimastem will announce its phase
I/IIa clinical trial results (end of 2020). To our understanding,
these are positive but preliminary results and the final results
should be awaited; target price raised to 1.26 NIS. Full Report HERE
Electreon: (TASE: ELWS)
Startup Electreon recently won tender over
Volvo! The company continues to develop according to plan;
encouraging news from Europe is
released detailing policies to implement electric road solutions
like that of Electreon. Full Report HERE
Enlight: (TASE: ENLT)
Additional collaborations in Spain; Progress in all projects; Electricity
receipts totaled significant growth and totaled about NIS 229 million in the past year; Target price
increased to NIS 3.91. Full Report
HERE
DNA Biomedical Solutions: (TASE: DNA)
Entera Bio (NASDAQ:ENTX), subsidiary of DNA, nominated a new CEO
which will focus more on collaborations with big pharma; announced
initiation of phase 2 dose ranging study for oral PTH; target price
unchanged. Due to an ongoing arbitrage, investment in TASE:DNA
is a highly cost effective way to be exposed to Entera stock. Full
Report HERE
Media Contact:
Tiran
Rothman
Head of Frost Israel
Frost & Sullivan
+972-(0)9-950-2888
equity.research@frost.com
View original
content:http://www.prnewswire.com/news-releases/introducing-investors-to-breakthrough-hi-tech-and-bio-tech-companies-frost--sullivan-publishes-q2-coverage-for-investors-to-make-informed-decisions-300932917.html
SOURCE Frost & Sullivan